Speaker illustration

Doctor Murray David Polkinghorne

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Dr Murray Polkinghorne is a medical doctor with translational research experience in cardiometabolic disease, regenerative medicine and cardiac arrhythmias. He completed his medical degree (MBChB) at the University of Cape Town in 2017, during which he spent time as a research fellow in the McLeod and Behfar labs at the Mayo Clinic in Minnesota, USA. In 2018, he began a Masters in Philosophy (MPhil) in Translational Biomedical Research at the University of Cambridge, UK where he worked in the Sinha lab. In 2019, Murray received the Radcliffe Department of Medicine Scholarship and the Clarendon Fund Award to read for a Doctor of Philosophy (DPhil) in Medical Sciences at Balliol College, University of Oxford. He is currently in the Antoniades lab, where he is developing a translational research platform that uses genetic tools, mechanistic experiments and outcomes data to identify and validate novel therapies for patients with cardiometabolic disease.

Genetic variability of lipoprotein(a) controls vascular inflammation/redox signalling and predicts adverse cardiovascular outcomes in coronary artery disease

Event: ESC Congress 2023

Topic: Inflammation and Immunity

Session: Metabolic markers in chronic coronary syndrome


Adipose tissue derived ceramides regulate myocardial redox state and predict cardiovascular outcomes

Event: ESC Congress 2022

Topic: Metabolism

Session: Metabolism, mitochondria, and heart diseases


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb